Merrion Pharmaceuticals plc announces commencement of next stage

September 2008

Merrion Pharmaceuticals the TCD based Irish American company has confirmed that it has begun a joint feasibility study on oral drug delivery with Swiss based multinational Ferring Pharmaceuticals.

Merrion was set up by Life sciences venture capital group Growcorp when it acquired a basket of drug delivery technologies from Elan in 2002. It specialises in manufacturing oral versions of previously injectable only medicines.

The joint programme will test the efficiency of Merrion's technology to improve the oral absorption of drugs.

July 2008

Merrion Pharmaceuticals plc announces commencement of next stage of oral drug research collaboration programme with Novo Nordisk

Dublin, Ireland

Merrion Pharmaceuticals today announced the continuation of an oral drug delivery research collaboration programme with Novo Nordisk. This follows on from the completion of several oral feasibility studies combining Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) oral drug delivery technology with Novo Nordisk compounds. In continuation of this collaboration, Merrion will now complete the development of solid dosage forms with GIPET for additional testing.

″We are very pleased to be working on oral versions of Novo Nordisk′s compounds. We believe there can be substantial benefit to patients in having oral formulations on these compounds available - and our GIPET technology has shown the ability to significantly improve the oral delivery of these drugs. ″John Lynch, Merrion′s CEO said to-day.

Merrion was founded Growcorp Group Limited who acquired the Intellectual Property from Elan in 2004 created a business plan and recruited the senior management.

In more than 20 clinical studies, GIPET technology has been shown to improve the oral absorption of a wide range of drugs, by between 500% and 1500%. Drugs studied ranged from small molecules to small proteins. Merrion currently has four products in development, as well as several collaboration agreements with pharmaceutical partners, using this technology.


Copyright 2007 Growcorp Group. All Rights Reserved.
Office: Growcorp Group Limited, 3015 Lake Drive, Citywest Campus, Citywest, Dublin 24 | Telephone: +353 1 4661000 | Fax: +353 1 4661002
2009
Merrion’s new facility at Citywest officially opened by Minister Harney 29 October 2009. Growcorp the founding Shareholder of Merrion Pharmaceuticals the Irish Stock Exchange listed company today announced it was delighted with the opening by Merrion Pharmaceuticals of it new facility in Citywest.

Merrion Pharmaceuticals has purchased a new facility in order to expand its current research and development operations.
Merrion has acquired a 26,684 square foot pharmaceutical facility in Citywest, Co Dublin.

Merrion Lands Second $58M Deal. Irish drug development firm Merrion Pharmaceuticals has inked a second deal with Denmark-based medicine supplier Novo Nordisk that could be worth up to $58m (Eur44m) for the Dublin-headquartered company. Merrion was founded by Growcorp Group Ltd when it acquired extensive IP from Elan in early 2003 following over one years due diligence. Growcorp then developed a business plan and hired all senior management.

2008
Galway and Dublin. Wednesday, 3rd December, 2008: Growcorp Group, the Irish investment vehicle, will earn over Eur 7m following the acquisition this week of Irish theranoistic company Neutekbio by Danish biotechnology development company Merrion Pharmaceuticals has signed a multi-million euro deal with Novo Nordisk to develop oral diabetes products.

2008
DUBLIN, Ireland, Nov 5, 2008 an international specialty pharmaceutical company, today announced that it has been awarded the Frost & Sullivan 2008 Osteoporosis Technology Innovation of the Year Award

2008
DUBLIN, Ireland, Nov 5, 2008 an international specialty pharmaceutical company, today announced that it has been awarded the Frost & Sullivan 2008 Osteoporosis Technology Innovation of the Year Award

2008
Merrion Pharmaceuticals the TCD based Irish American company has confirmed that it has begun a joint feasibility study on oral drug delivery with Swiss based multinational Ferring Pharmaceuticals.

2007
Merrion Pharmaceuticals Plc was admitted to the IEX today and commenced
unconditional trading.........